Clinical effect of triple therapy combined with Saccharomyces boulardii in the treatment of Helicobacter pylori infection in children

Chinese Journal of Contemporary Pediatrics

Volumn 16, Issue 3, 2014, Pages 230-233

  Zhao, Hong Mei ^a   Ou Yang, Hong Juan ^a   Duan, Bo Ping ^a   Xu, Bin ^a   Chen, Zhi Yong ^a   Tang, Juan ^a   You, Jie Yu ^a  

^a HUNAN CHILDREN'S HOSPITAL   (China)

Author keywords

Child; Helicobacter pylori; Saccharomyces boulardii; Triple therapy

Indexed keywords

AMOXICILLIN; CARBON 13; CLARITHROMYCIN; OMEPRAZOLE; PROBIOTIC AGENT;

ABDOMINAL PAIN; ADD ON THERAPY; ARTICLE; BACTERIAL CLEARANCE; BREATH ANALYSIS; CHILD; CLINICAL EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; HELICOBACTER INFECTION; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SACCHAROMYCES BOULARDII; STOMATITIS; TREATMENT DURATION; VOMITING;

AMOXICILLIN; CHILD; CHILD, PRESCHOOL; CLARITHROMYCIN; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; OMEPRAZOLE; PROBIOTICS; PROSPECTIVE STUDIES; SACCHAROMYCES;

EID: 84901701743     PISSN: 10088830     EISSN: None     Source Type: Journal    
DOI: 10.7499/j.issn.1008-8830.2014.03.002     Document Type: Article

References (14)

1. Go MF, Crowe SE. Virulence and pathogenicity of Helicobacter pylori[J]. Gastroenterol Clin North Am, 2000, 29(3): 649-670.
2. Malfertheine P, Megraud F, O' Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report[J]. Gut, 2007, 56(6): 772-781. (Pubitemid 46854190)
3. Lionetti E, Indrio F, Pavone L, et al. Role of probiotics in pediatric patients with Helicobacter pylori infection: a comprehensive review of the literature[J]. Helicobacter, 2010, 15(2): 79-87.
4. Scaccianoce G, Zullo A, Hassan C, et al. Triple therapies plus different probiotics for Helicobacter pylori eradicaton[J]. Eur Rev Med Pharmacol Sci, 2008, 12(4): 251-256.
5. Vandenplas Y, Brunser O, Szajewska H. Saccharomyces boulardii in childhood[J]. Eur J Pediatr, 2009, 168(3): 253-265.
6. Rowland M, Daly L, Vaughan M, et al. Age-specific incidence of Helicobacter pylori[J]. Gastroenterology, 2006, 130(1): 65-72. (Pubitemid 43049836)
7. Wizla-Derambure N, Michaud L, Ategbo S, et al. Familial and community environmental risk factors for Helicobacter pylori infection in children and adolescents[J]. J Pediatr Gastroenterol Nutr, 2001, 33(1): 58-63. (Pubitemid 32706125)
8. Oderda G, Shcherbakov P, Bontems P, et al. European Pediatric Task Force on Helicobacter pylori. Results from the pediatric European register for treatment of Helicobacter pylori (PERTH)[J]. Helicobacter, 2007, 12(2): 150-156.
9. Gotteland M, Poliak L, Cruchet S, et al. Effect of regular ingestion of Saccharomyces boulardii plus inulin or Lactobacillus acidophilus LB in children colonized by Helicobacter pylori[J]. Acta Pediatrica, 2005, 94(12): 1-6.
10. de Bortoli N, Leonardi G, Ciancia E, et al. Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferin and probiotics[J]. Am J Gastroenterol, 2007, 102(5): 951-956. (Pubitemid 46698221)
11. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardiisupplementation on Helicobacter pylori eradication rates and side effects during treatment[J]. Aliment Pharmacol Ther, 2010, 32(9): 1069-1079.
12. Tong JL, Ran ZH, Shen J, et al. Meta-analysis: the effect of supplementation with probiotics on eradicationrates and adverse events during Helicobacter pylori eradication therapy[J]. Aliment Pharmacol Ther, 2007, 25(2): 155-168. (Pubitemid 46046372)